Faeth Therapeutics (FTH) investor relations material

Introduction and agenda

• Inaugural analyst and investor event covered PIKTOR’s scientific rationale, preclinical and translational data, clinical development, market opportunity, and Q&A.

• PIK-201 is a Phase II trial in endometrioid endometrial cancer; PIK-101 is a Phase Ib/II study in HR-positive, HER2-negative advanced breast cancer.

KOL background and credentials

• Scientific co-founder Marcus Goncalves directs NYU’s Holman Division of Endocrinology, Diabetes, and Metabolism and researches systemic metabolism and PAM pathway biology.

• Oliver Maddocks is co-founder and CSO, and an Honorary Professor of Cancer Biology and Metabolism at the University of Glasgow.

• Scientific founders and advisors include Lewis Cantley, Sid Mukherjee, Karen Vousden, Scott Lowe, Greg Hannon, and medicinal chemist Kevan Shokat.

• CMO Debbie Chirnomas has academic and clinical experience at Yale and oncology development roles at Pfizer, Gamida Cell, and Arvinas.

Market insights and analysis

• PAM alterations occur in up to half of solid tumors and in ~80% of endometrial cancers; only 8% of tumors are addressable by mutant-selective agents, per the presentation.

• Endometrial cancer has ~68,000 new U.S. cases annually and ~9,000 estimated annual post-immunotherapy 2L+ patients; modeled U.S. opportunity is ~$1.5B.

• HR+/HER2− disease is ~70% of breast cancer; modeled annual U.S. 2L populations are ~12,000 PI3K-mutant and ~18,000 PI3K-wild-type patients, with respective TAMs of ~$2B and ~$3B.

• Endometrial cancer incidence rose 26% and mortality 36% over the prior decade; metastatic 5-year survival is ~20%, and 2L+ care has no consensus standard.

• Topo I ADCs are moving earlier in treatment; prior Topo I ADC exposure is allowed in PIK-201, and Phase III eligibility is being designed to include these patients.